Shattuck Labs, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Shattuck Labs, Inc. (STTK) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $132.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-05-07
- Shattuck Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $132.00K, a 11.86% increase year-over-year.
- Shattuck Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $132.00K, a 16.81% increase year-over-year.
- Shattuck Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $133.00K, a 22.02% increase year-over-year.
- Shattuck Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $123.00K, a 17.14% increase year-over-year.
- Shattuck Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $506.00K, a 18.22% increase from fiscal 2024.
- Shattuck Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $428.00K, a 17.58% increase from fiscal 2023.
- Shattuck Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $364.00K, a 20.53% increase from fiscal 2022.
- Shattuck Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $302.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $132.00K 10-Q · filed 2026-05-07 | $264.00K derived: sum of 2 quarters · filed 2026-05-07 | $397.00K derived: sum of 3 quarters · filed 2026-05-07 | $520.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $265.00K derived: sum of 2 quarters · filed 2026-03-05 | $388.00K derived: sum of 3 quarters · filed 2026-03-05 | $506.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $256.00K derived: sum of 2 quarters · filed 2025-11-06 | $374.00K 10-Q · filed 2025-11-06 | $487.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $241.00K 10-Q · filed 2025-08-14 | $354.00K derived: sum of 3 quarters · filed 2026-05-07 | $463.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | $118.00K 10-Q · filed 2026-05-07 | $231.00K derived: sum of 2 quarters · filed 2026-05-07 | $340.00K derived: sum of 3 quarters · filed 2026-05-07 | $445.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $222.00K derived: sum of 2 quarters · filed 2026-03-05 | $327.00K derived: sum of 3 quarters · filed 2026-03-05 | $428.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $214.00K derived: sum of 2 quarters · filed 2025-11-06 | $315.00K 10-Q · filed 2025-11-06 | $412.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $206.00K 10-Q · filed 2025-08-14 | $303.00K derived: sum of 3 quarters · filed 2025-08-14 | $395.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $101.00K 10-Q · filed 2025-05-01 | $198.00K derived: sum of 2 quarters · filed 2025-05-01 | $290.00K derived: sum of 3 quarters · filed 2025-05-01 | $380.00K derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $189.00K derived: sum of 2 quarters · filed 2025-03-27 | $279.00K derived: sum of 3 quarters · filed 2025-03-27 | $364.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $182.00K derived: sum of 2 quarters · filed 2024-11-14 | $267.00K 10-Q · filed 2024-11-14 | $349.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $175.00K 10-Q · filed 2024-08-01 | $257.00K derived: sum of 3 quarters · filed 2024-08-01 | $336.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $85.00K 10-Q · filed 2024-05-02 | $167.00K derived: sum of 2 quarters · filed 2024-05-02 | $246.00K derived: sum of 3 quarters · filed 2024-05-02 | $322.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $161.00K derived: sum of 2 quarters · filed 2024-02-29 | $237.00K derived: sum of 3 quarters · filed 2024-02-29 | $302.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $155.00K derived: sum of 2 quarters · filed 2023-11-09 | $220.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $141.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $65.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-02-23 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |